Abstract：
:Hypoxia is a critical hallmark of solid tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen (HBO) treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, by enhancing the amount of dissolved oxygen in the plasma and thereby increasing O(2) delivery to the tissue. Studies on HBO and cancer have up to recently focused on whether enhanced oxygen acts as a cancer promoter or not. As oxygen is believed to be required for all the major processes of wound healing, one feared that the effects of HBO would be applicable to cancer tissue as well and promote cancer growth. Furthermore, one also feared that exposing patients who had been treated for cancer, to HBO, would lead to recurrence. Nevertheless, two systematic reviews on HBO and cancer have concluded that the use of HBO in patients with malignancies is considered safe. To supplement the previous reviews, we have summarized the work performed on HBO and cancer in the period 2004-2012. Based on the present as well as previous reviews, there is no evidence indicating that HBO neither acts as a stimulator of tumor growth nor as an enhancer of recurrence. On the other hand, there is evidence that implies that HBO might have tumor-inhibitory effects in certain cancer subtypes, and we thus strongly believe that we need to expand our knowledge on the effect and the mechanisms behind tumor oxygenation.
journal_name
Target Oncoljournal_title
Targeted oncologyauthors
Moen I,Stuhr LEdoi
10.1007/s11523-012-0233-xsubject
Has Abstractpub_date
2012-12-01 00:00:00pages
233-42issue
4eissn
1776-2596issn
1776-260Xjournal_volume
7pub_type
杂志文章,评审abstract：:Several angiogenesis inhibitors have been approved for commercial use and many additional agents are under development for the treatment of various malignancies. Cardiovascular toxicities have been increasingly recognized as effects of this entire class of new anticancer therapeutics. There is a limited but growing un...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-009-0106-0
更新日期：2009-04-01 00:00:00
abstract：BACKGROUND:Serum protein fraction (SPF) is a common parameter reflecting the nutritional and inflammatory status of the human body. However, its role in patients with cancer, particularly those treated with targeted agents, is unknown. OBJECTIVE:We conducted this study to explore the prognostic value of SPF in patient...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-019-00625-9
更新日期：2019-04-01 00:00:00
abstract：:The ubiquitin (Ub)+proteasome proteolytic pathway is responsible for the selective degradation of the majority of nuclear and cytosolic proteins. The proteasome is a high molecular weight multicatalytic protease that serves as the catalytic core of the complex Ub-dependent protein degradation pathway and is an excitin...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-010-0165-2
更新日期：2010-12-01 00:00:00
abstract：:Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agen...
journal_title：Targeted oncology
pub_type： 杂志文章,meta分析,评审
doi：10.1007/s11523-011-0201-x
更新日期：2011-12-01 00:00:00
abstract：:In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs). Determining genotypes in TKI-resistant GISTs is challenging due to the potential risks and limitations of repeated biopsies ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-015-0361-1
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:The prognosis of patients with advanced pancreatic cancer is dismal, and there is a need for novel and effective treatments. OBJECTIVES:Tο determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a novel gemcitabine (G) and temsirolimus (T) combination (phase I) and estimate the 6-m...
journal_title：Targeted oncology
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1007/s11523-018-0605-y
更新日期：2018-12-01 00:00:00
abstract：:Differentiated thyroid carcinoma is the most frequent neoplasm of the endocrine system. Although thyroid cancer usually has an excellent prognosis, no therapeutic options are available for patients that develop metastases and are or became resistant to radioiodine therapy. The deeper knowledge of molecular aberrations...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-009-0124-y
更新日期：2009-12-01 00:00:00
abstract：:Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tu...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-012-0216-y
更新日期：2012-06-01 00:00:00
abstract：BACKGROUND:A consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO). OBJECTIVE:Since serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-018-0599-5
更新日期：2018-12-01 00:00:00
abstract：:In anticancer drug development, there has been increasing consideration for the potential of a compound to cause adverse electrocardiographic changes, especially QT interval prolongation, which can be associated with risk of torsades de pointes and sudden death. Irrespective of overt clinical toxicities, QTc assessmen...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-014-0325-x
更新日期：2015-03-01 00:00:00
abstract：:The selective BRAF inhibitors vemurafenib and dabrafenib yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma. Treatment traditionally continues until disease progression or the development of unacceptable toxicity. Acquired drug resistance and toxicity are key...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-015-0410-9
更新日期：2016-08-01 00:00:00
abstract：:Basal transcription regulation of the epidermal growth factor receptor is dependent upon a CA simple sequence repeat polymorphism in the intron-1 (CA-SSR-1). Here, we evaluate the role of CA-SSR-1 in complete resected esophageal cancer (EC) patients without neoadjuvant or adjuvant treatment. Genomic DNA was extracted ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-013-0260-2
更新日期：2014-03-01 00:00:00
abstract：:The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00715-z
更新日期：2020-06-01 00:00:00
abstract：BACKGROUND:Golgi phosphoprotein 2 (GOLPH2) has been shown to be involved in chronic inflammatory processes and carcinogenesis. GOLPH2 is prominently overexpressed in hepatocellular carcinoma, melanoma, glioblastoma, prostate, lung, and colorectal cancer. With a low and tightly regulated expression in non-malignant tiss...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-019-00667-z
更新日期：2019-10-01 00:00:00
abstract：BACKGROUND:Cancer is a multifactorial disease, which makes it difficult to cure. Since more than one defective cellular component is often involved during oncogenesis, combination therapy is gaining prominence in the field of cancer therapeutics. OBJECTIVE:The purpose of this study was to investigate the combinatorial...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-016-0441-x
更新日期：2016-10-01 00:00:00
abstract：BACKGROUND:In 2017, nivolumab monotherapy was shown to be effective as third- or later-line therapy in patients with advanced gastric or gastroesophageal junction cancer. OBJECTIVE:In this study, we investigated the relationship between the neutrophil-to-lymphocyte ratio (NLR) and the outcomes of nivolumab monotherapy...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00716-y
更新日期：2020-06-01 00:00:00
abstract：:Mesothelin is a tumor differentiation antigen, which is highly expressed in several solid neoplasms, including pancreatic cancer. Its selective expression on malignant cells and on only a limited number of healthy tissues has made it an interesting candidate for investigation as a diagnostic and prognostic biomarker a...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-018-0567-0
更新日期：2018-06-01 00:00:00
abstract：:It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies. Strategies are being developed to block IGF-1R as an anticancer treatment. We reviewed several potential strategies for disrupting th...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-009-0123-z
更新日期：2009-12-01 00:00:00
abstract：BACKGROUND:Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations. OBJECTIVE:The purpose of this study was to assess...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-017-0497-2
更新日期：2017-08-01 00:00:00
abstract：:Venetoclax (Venclyxto®; Venclexta®) is a first-in-class, oral, selective B cell lymphoma-2 (BCL-2) inhibitor. The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL); the specific indication(s)...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-019-00673-1
更新日期：2019-10-01 00:00:00
abstract：:Chemotherapy represents the mainstay of non-small cell lung cancer (NSCLC) treatment, but response is usually observed in only one out of three patients. Massive efforts have been carried out to identify biomarkers that might help clinicians to choose appropriate drugs, by identifying potentially sensitive subjects an...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-010-0132-y
更新日期：2010-03-01 00:00:00
abstract：:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall surviva...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0484-7
更新日期：2017-04-01 00:00:00
abstract：BACKGROUND:Immune checkpoint inhibitors (ICIs) demonstrated improved overall survival (OS) in heavily pretreated unselected patients with metastatic gastro-esophageal junction (mGOJ)/gastric cancer (GC). Attempts to select patients based on programmed death-ligand 1 (PD-L1) expression appear to be suboptimal. A strong ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00723-z
更新日期：2020-06-01 00:00:00
abstract：:The advent of imatinib mesilate, an oral target therapy, has dramatically changed the natural history of gastrointestinal stromal tumours (GISTs). This rare neoplasm has become the paradigm of targeted therapies in solid tumours, also introducing a home-based cure concept in oncology. However, it should be retained th...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-012-0221-1
更新日期：2012-12-01 00:00:00
abstract：:Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib. Retrospective studies documented the same bene...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-010-0163-4
更新日期：2010-12-01 00:00:00
abstract：:The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC marke...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-013-0290-9
更新日期：2014-09-01 00:00:00
abstract：:Atezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-019-00686-w
更新日期：2019-12-01 00:00:00
abstract：:Obinutuzumab (Gazyva®, Gazyvaro®) is a recombinant, monoclonal, humanized and glycoengineered, type II, anti-CD20, IgG1 antibody. It has recently been granted an additional indication for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. In the...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0485-6
更新日期：2017-04-01 00:00:00
abstract：:Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotox...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-016-0452-7
更新日期：2017-02-01 00:00:00
abstract：:The currently prevalent somatic mutation theory of carcinogenesis and metastases explicitly assumes that cancer is a cellular disease, i.e. a disease of the control of cell proliferation and/or cell differentiation. Accordingly, explanations should always be sought for at a gene and/or gene product level, regardless o...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-013-0277-6
更新日期：2013-06-01 00:00:00
